Cargando…
Dual-Antigen COVID-19 Vaccine Subcutaneous Prime Delivery With Oral Boosts Protects NHP Against SARS-CoV-2 Challenge
We have developed a dual-antigen COVID-19 vaccine incorporating genes for a modified SARS-CoV-2 spike protein (S-Fusion) and the viral nucleocapsid (N) protein with an Enhanced T-cell Stimulation Domain (N-ETSD) to increase the potential for MHC class II responses. The vaccine antigens are delivered...
Autores principales: | Gabitzsch, Elizabeth, Safrit, Jeffrey T., Verma, Mohit, Rice, Adrian, Sieling, Peter, Zakin, Lise, Shin, Annie, Morimoto, Brett, Adisetiyo, Helty, Wong, Raymond, Bezawada, Ashish, Dinkins, Kyle, Balint, Joseph, Peykov, Victor, Garban, Hermes, Liu, Philip, Bacon, Andrew, Bone, Pete, Drew, Jeff, Sanford, Daniel C., Spilman, Patricia, Sender, Lennie, Rabizadeh, Shahrooz, Niazi, Kayvan, Soon-Shiong, Patrick |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8481919/ https://www.ncbi.nlm.nih.gov/pubmed/34603305 http://dx.doi.org/10.3389/fimmu.2021.729837 |
Ejemplares similares
-
Intranasal plus subcutaneous prime vaccination with a dual antigen COVID-19 vaccine elicits T-cell and antibody responses in mice
por: Rice, Adrian, et al.
Publicado: (2021) -
Identification of an immune gene expression signature associated with favorable clinical features in Treg-enriched patient tumor samples
por: Givechian, Kevin B., et al.
Publicado: (2018) -
CAD/POLD2 gene expression is associated with poor overall survival and chemoresistance in bladder urothelial carcinoma
por: Givechian, Kevin B., et al.
Publicado: (2018) -
Heterologous saRNA Prime, DNA Dual-Antigen Boost SARS-CoV-2 Vaccination Elicits Robust Cellular Immunogenicity and Cross-Variant Neutralizing Antibodies
por: Rice, Adrian, et al.
Publicado: (2022) -
An ACE2 Triple Decoy that neutralizes SARS-CoV-2 shows enhanced affinity for virus variants
por: Tanaka, Shiho, et al.
Publicado: (2021)